Interferon and ribavirin for patients with chronic hepatitis C who did not respond to previous interferon therapy: A meta-analysis of controlled and uncontrolled trials

Hepatology

Volumn 33, Issue 1, 2001, Pages 231-240

  Cheng, Steve J ^a   Bonis, Peter A L ^a   Lau, Joseph ^a   Pham, Nhu Q ^a   Wong, John B ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; RIBAVIRIN; VIRUS RNA;

ARTICLE; CHRONIC HEPATITIS; CLINICAL TRIAL; DRUG EFFICACY; FOLLOW UP; GENOTYPE; HEPATITIS C; HUMAN; META ANALYSIS; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT OUTCOME; VIRUS LOAD;

EID: 0035153627     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2001.20675     Document Type: Article

References (90)

1. Hepatitis C
2. IFN alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
3. Randomised trial of interferon alpha2b plus ribavilin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
4. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C
5. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C
6. Management of hepatitis C
7. Meta-analysis in clinical trials
8. A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C
9. Combined treatment with interferon alpha-2b and ribavirin for chronic hepatitis C in patients with a previous non-response or non-sustained response to interferon alone
10. A randomized trial of ribavirin and interferon-alpha vs. interferon-alpha alone in patients with chronic hepatitis C who were nonresponders to a previous treatment
11. Interferon versus ribavirin plus interferon in chronic hepatitis C previously resistant to interferon: A randomized trial
12. Treatment with ribavirin + alpha interferon in HCV chronic active hepatitis non-responders to interferon alone: Preliminary results
13. Pilot study of a short course of ribavirin and alpha interferon in the treatment of chronic active hepatitis C not responding to alpha-interferon alone
14. Changes in serum hepatitis C virus RNA in interferon nonresponders retreated with interferon plus ribavirin: A preliminary report
15. Re-treatment with interferon-alpha and ribavirin in primary interferon-alpha non-responders with chronic hepatitis C
16. Interferon alpha plus ketoprofen or interferon alpha plus ribavirin in chronic hepatitis C non-responder to interferon alpha alone: Results of a pilot study
17. Interferon-alpha-2B and ribavirin in combination for chronic hepatitis C patients not responding to interferon-alpha alone: An Italian multicenter, randomized, controlled, clinical study
18. Interferon alpha-2B and ribavirin in combination for patients with chronic hepatitis C who failed to respond to, or relapsed alter, interferon alpha therapy: A randomized trial
19. Ribavirin and interferon-alpha combination therapy vs interferon-alpha alone in the re-treatment of chronic hepatitis C: A randomized clinical trial
20. Combination antiviral therapy with ribavirin and interferon alfa in interferon alfa relapsers and non-responders: Italian experience
21. Sequential versus concomitant administration of ribavirin and interferon alfa-n3 in patients with chronic hepatitis C not responding to interferon alone: Results of a randomized, controlled trial
22. Treatment with interferon-alpha2a alone or interferon-alpha2a plus ribavirin in patients with chronic hepatitis C previously treated with interferon-alpha2a
23. Interferon-alpha plus ribavirin in chronic hepatitis C resistant to previous interferon-alpha course: Results of a randomized multicenter trial
24. Re-treatment of non-responder or relapser chronic hepatitis C patients with interferon plus ribavirin vs interferon alone
25. Interferon plus ribavirin in chronic hepatitis C non-responders to recombinant alpha-interferon
26. Combination treatment with interferon alfa-2b and ribavirin for chronic hepatitis C in patients who have failed to achieve sustained response to interferon alone: Swedish experience
27. Combination treatment of alpha interferon-2b (alpha IFN) and ribavirin in chronic hepatitis C genotype 4 patients resistant to interferon therapy
28. Interferon alpha with ribavirin for the treatment of chronic hepatitis C in non-responders or relapsers to interferon monotherapy
29. Is combination therapy of chronic hepatitis C with interferon alpha and ribavirin in primary interferon nonresponders indicated? - An analysis of personal experiences and review of the literature
30. Chronic hepatitis C non responder patients to interferon: Results after stopping one year of interferon plus ribavirin combination
31. High dose interferon alfa-2a plus ribavirin for the treatment of chronic hepatitis C: Preliminary results of a multicenter trial
32. Ribavirin + alpha-IFN in patients with chronic hepatitis C genotype 1b non responder to alpha-IFN
33. Dynamic of response to IFN plus ribavirin in relapsers and non responders with chronic hepatitis C
34. The Colorado hepatitis treatment group: Early results of the use of combination interferon-alfa-2b (Intron-A) plus ribavirin (Rebetol) in the treatment of nonresponders
35. Interim results of the Washington, DC metropolitan area study of IFN alfa-2b (Intron A) plus ribavirin (RIBA) for prior non-responders (NR) and relapsers (RLP) with chronic hepatitis C
36. High response rate to interferon/ribavirin (INF/RIB) treatment in HCV relapsers but not in non-responders
37. Interferon plus ribavirin re-treatment in patients with chronic hepatitis C
38. High rate of complete response to combination therapy in patients with chronic hepatitis C (CHC) refractory to interferon alfa
39. Combination therapy with interferon and ribavirin for chronic hepatitis C patients resistant to alfa interferon
40. Long term interferon and ribavirin combination therapy in chronic hepatitis C patients unresponsive to interferon monotherapy
41. r-Interferon alfa-2b/ribavirin combined therapy followed by low-dose r-interferon alfa-2b in chronic hepatitis C interferon nonresponders
42. Response to 12-month treatment with interferon alfa-2B (INF a-2B) plus ribavirin in patients with chronic hepatitis C relapsers or non responders to a previous INF treatment
43. Alpha-interferon plus ribavirin for the treatment of chronic hepatitis C in patients who have failed treatment with alpha-interferon
44. High dose interferon + ribavirin combination re-treatment is cost-effective in patients with HCV genotype other than I who failed to respond to interferon monotherapy
45. Combination therapy with interferon-alfa2B and ribavirin for the treatment of nonresponder and relapse patients with chronic hepatitis C: A multicentre study
46. Response rates to combination therapy in previously treated hepatitis C patients, both relapsers and nonresponders, in an urban tertiary care center - Interim results
47. The significance of HCV RNA "breakthrough" in Rebetron therapy
48. Rebatron therapy of chronic hepatitis C patients who were non-responsive or relapsed on interferon monotherapy
49. Combination therapy with interferon-alfa-2B (Intron-A) and ribavirin (Rebetol) in chronic hepatitis C patients previously relapsing or not responding to interferon alone
50. Interim analysis of a multi-center trial of ribavirin plus interferon (INF) alfa 2B in patients with chronic hepatitis C previously treated with interferon only
51. Response to re-treatment with interferon/ribavirin in Caucasian and African American relapsers and nonresponders
52. Interim results of the NYNEST interferon-ribavirin retreatment trial-in chronic hepatitis C non-responders
53. Interferon alfa-2b and ribavirin in patients with resistant chronic hepatitis C
54. Interferon-ribavirin combination: Sustained response in previous monotherapy non-responders
55. Interferon alpha-2B and ribavirin for interferon monotherapy nonresponders
56. Multicenter, placebo-controlled, double-blind trial of interferon alpha-2B plus ribavirin vs. interferon alone for re-treatment of non-responders and relapsers with chronic hepatitis C who have failed previous treatment with interferon: A 48 week review
57. In HCV non-responders: Combination therapy is more effective than induction therapy in achieving viral clearance
58. HCV nonresponders: Standard combination therapy versus an induction regimen of high dose interferon alfa-2B (IFN) with ribavirin (RIB)
59. Interferon plus ribavirin (6 vs 12 months) in chronic hepatitis C patients non responders to interferon alone
60. Interferon plus ribavirin vs interferon alone in HCV chronic liver disease non responder to a previous cycle of interferon alone
61. Response to triple antiviral therapy in interferon non-responders with chronic hepatitis C
62. Ribavirin and interferon re-treatment of HCV chronic patients non responder to interferon
63. Re-treatment of chronic hepatitis C (CHC) with sequential interferon-ribavirin combination (IFN-RIBA) therapy
64. Ribavirin and alpha-interferon in patients with chronic hepatitis C not responding to interferon alone
65. Re-treatment of chronic hepatitis C with ribavirin and interferon alpha: A study in non-responding and relapsing group of patients
66. Can interferon-ribavirin effectively treat patients who did not respond to a first conventional therapy by interferon?
67. Ribavirin plus alfaIFN in the treatment of non-responder or relapser patients with chronic hepatitis C
68. Efficacy of interferon (IFN) in combination with ribavirin in chronic hepatitis C patients not responding or relapsing to IFN alone
69. Therapeutic efficacy of interferon + ribavirin (IFN+R), 6 vs. 12 months, in chronic hepatitis C (CH-C) patients who were non-responders (NR) or relapsers (RR) to a previous treatment with interferon
70. Therapy of hepatitis C in interferon non-responders. Results of a pilot study comparing interferon vs. interferon/ribavirin after iron depletion
71. Interferon plus ribavirin re-treatment during 12 months in patients with chronic hepatitis C
72. Alpha interferon 2b plus ribavirin in interferon non-responders or relapsing chronic hepatitis C patients
73. Re-treatment with interferon plus ribavirin in patients affected by chronic hepatitis C
74. Interferon-alfa (IFNalfa) + Ribavirin (RIBA) therapy for chronic hepatitis C (CHC) patients, non responders (NRs) to IFNalfa monotherapy
75. Double-blind placebo controlled Study of interferon versus interferon plus ribavirin for the treatment of hepatitis C in patients who previously failed interferon monotherapy
76. Therapeutic efficacy of reinforced vs. standard combination therapy schedule (IFN alfa2B + ribavirin) in chronic hepatitis C patients not responding or relapsing tO IFN alone
77. Interim analysis of a randomized controlled trial of combination of ribavirin and high dose interferon-alpha in interferon nonresponders with chronic hepatitis C
78. High dose of interferon α (IFN) plus ribavirin (RIBA) for 6 or 12 months in non repsonder (NR) patients with chronic hepatitis C (CHC): Results of a randomized trial
79. Interferon alfa plus ribavirin in chronic hepatitis C relapsers and non-responders to previous interferon alfa course
80. Re-treatment of chronic hepatitis C patients with interferon plus ribavitin vs interferon alone
81. Re-treatment of IFN nonresponders (NR) or relapsers (REL) with chronic hepatitis C with high dose interferon (IFN) in combination with ribavirin
82. Quantification of serum hepatitis C virus RNA with daily or standard interferon doses plus ribavirin in nonresponder patients with chronic hepatitis C
83. Interferon and ribavirin versus interferon and amantadine in interferon
84. Interferon alfa-2b plus fibavirin for chronic hepatitis C patients who have not responded to interferon monotherapy
85. Interferon-alpha-2b + ribavirin for the treatment of chronic hepatitis C in non-responders to interferon-alpha-monotherapy
86. Effect of 12 month alfa-IFN and ribavirin combination therapyin chronic hepatitis C unresponsive to alfa-IFN
87. Treatment of chronic hepatitis C in patients who failed interferon monotherapy: Effects of higher doses of interferon and ribavirin combination therapy
88. Factors predictive of a beneficial response to therapy of Hepatitis C
89. Meta-analysis in epidemiology, with special reference to studies of the association between exposure to environmental tobacco smoke and lung cancer: A critique